Complete financial analysis of Miromatrix Medical Inc. (MIRO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Miromatrix Medical Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- KBC Global Limited (KBCGLOBAL.NS) Income Statement Analysis – Financial Results
- Sagarsoft (India) Limited (SAGARSOFT.BO) Income Statement Analysis – Financial Results
- Schaeffler AG (SHA0.DE) Income Statement Analysis – Financial Results
- GreenFirst Forest Products Inc. (GFP.TO) Income Statement Analysis – Financial Results
- BSR Real Estate Investment Trust (BSRTF) Income Statement Analysis – Financial Results
Miromatrix Medical Inc. (MIRO)
About Miromatrix Medical Inc.
Miromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. Its proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. The company has collaborations with The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc. was incorporated in 2009 and is headquartered in Eden Prairie, Minnesota.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 953.47K | 33.07K | 46.53K | 250.00K |
| Cost of Revenue | 500.00K | 500.00K | 500.00K | 250.00K |
| Gross Profit | 453.47K | -466.93K | -453.47K | 0.00 |
| Gross Profit Ratio | 47.56% | -1,412.13% | -974.58% | 0.00% |
| Research & Development | 18.30M | 10.75M | 7.28M | 6.27M |
| General & Administrative | 8.72M | 4.64M | 2.11M | 2.44M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.72M | 4.64M | 2.11M | 2.44M |
| Other Expenses | 3.68M | 705.59K | -577.06K | -142.86K |
| Operating Expenses | 30.70M | 16.10M | 8.81M | 8.56M |
| Cost & Expenses | 31.20M | 16.60M | 9.31M | 8.81M |
| Interest Income | 333.47K | 1.97K | 8.73K | 106.43K |
| Interest Expense | 47.73K | 676.52K | 765.17K | 48.39K |
| Depreciation & Amortization | 333.47K | 171.37K | -1.19M | -142.56K |
| EBITDA | -29.91M | -16.79M | -11.45M | -9.13M |
| EBITDA Ratio | -3,137.20% | -50,771.66% | -24,598.53% | -3,653.69% |
| Operating Income | -30.25M | -16.96M | -10.26M | -8.99M |
| Operating Income Ratio | -3,172.17% | -51,289.94% | -22,047.17% | -3,596.67% |
| Total Other Income/Expenses | 404.43K | 2.29M | -51.02K | -535.08K |
| Income Before Tax | -29.96M | -14.67M | -10.31M | -9.53M |
| Income Before Tax Ratio | -3,142.21% | -44,368.10% | -22,156.82% | -3,810.70% |
| Income Tax Expense | 47.84K | 284.98K | -1.59M | -6.46M |
| Net Income | -30.01M | -14.96M | -8.72M | -3.07M |
| Net Income Ratio | -3,147.22% | -45,229.95% | -18,732.75% | -1,228.07% |
| EPS | -1.45 | -1.30 | -0.82 | -0.29 |
| EPS Diluted | -1.45 | -1.30 | -0.82 | -0.29 |
| Weighted Avg Shares Out | 20.73M | 11.48M | 10.57M | 10.48M |
| Weighted Avg Shares Out (Dil) | 20.73M | 11.48M | 10.57M | 10.48M |
United Therapeutics to Acquire Miromatrix Medical
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. & EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today a definitive agreement for United Therapeutics to acquire Miromatrix. Miromatrix is a life sciences company...
Miromatrix to Present at the 2023 ISODP Organ Donation Congress
EDEN PRAIRIE, Minn., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that it will be...
Miromatrix CEO Jeff Ross to Present at the 2023 Cell & Gene Meeting on the Mesa
EDEN PRAIRIE, Minn., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that CEO Jeff Ross...
Miromatrix Announces Participation in H.C. Wainwright Global Investment Conference
EDEN PRAIRIE, Minn., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced its participation in the H.C....
Miromatrix Announces Participation in the ARM Tissue Engineering and Therapeutics Workshop
EDEN PRAIRIE, Minn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced its participation in the upcoming...
Miromatrix Medical Inc. (MIRO) Q2 2023 Earnings Call Transcript
Miromatrix Medical Inc. (NASDAQ:MIRO ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Max Forgan - Gilmartin Investor Relations Jeff Ross - Chief Executive Officer Jim Douglas - Chief Financial Officer Conference Call Participants Alex...
Miromatrix Reports Second Quarter 2023 Results and Provides Corporate Update
EDEN PRAIRIE, Minn., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported second quarter 2023 financial...
Miromatrix to Report Second Quarter 2023 Financial Results
EDEN PRAIRIE, Minn., July 25, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will...
Miromatrix Poster Voted Best in Congress at the 2023 American Transplant Congress; Jack Lake Wins Lifetime Achievement Award
EDEN PRAIRIE, Minn., July 13, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced that its poster entitled Initial...
Miromatrix Announces Participation in the 20th Annual Craig-Hallum Institutional Investor Conference
EDEN PRAIRIE, Minn., May 30, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced that members of the management...
Source: https://incomestatements.info
Category: Stock Reports